Cooper, D. et al. 2018. A POPULATION-BASED COST-EFFECTIVENESS ANALYSIS OF OLANZAPINE AND RISPERIDONE AMONG AMBULATORY PATIENTS WITH SCHIZOPHRENIA. Journal of Population Therapeutics and Clinical Pharmacology. 15, 3 (Dec. 2018).